Our findings suggest that measuring serum free IGF-I levels could contribute to the decision of whether or not to change the GH dose when high immunoreactive IGF-I levels are found in a GH-treated child with PWS, particularly when our results are confirmed in another study. Here, IGF1 is linked to Prader-Willi syndrome.